GNHAF News and Press, Vifor Pharma AG

China has the world’s largest iron deficiency anemia population with estimated prevalence of 15% 1 Approval may also benefit the Chinese healthcare system, among others through implementation of a more effective patient blood management (PBM) L...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

Vifor Pharma (OTCPK:GNHAY) and its partner American Regent, a Daiichi Sankyo Group company, have reached settlement agreements with Mylan Laboratories and Sandoz that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the FDA to market a...

The PDUFA action date for Cara’s main drug KORSUVA (treats pruritus) is August 23, 2021. If KORSUVA is approved, Cara would have sole access to a large patient market with no FDA-approved therapy. I calculate Cara to be extremely undervalued by P/S and PEG valuations and as...

Vifor Pharma AG (GNHAF) Q2 2021 Earnings Conference Call August 5, 2021, 8:00 am ET Company Participants Colin Bond - CFO Klaus Jensen - CMO Conference Call Participants Christian Glennie - Stifel James Gordon - JPMorgan Rosie Turner - Barclays Paul Verbraeken - Research Partners Barbora Blah...

The following slide deck was published by Vifor Pharma AG in conjunction with their 2021 Q2 earnings call. For further details see: Vifor Pharma AG 2021 Q2 - Results - Earnings Call Presentation

Cara Therapeutics (CARA) and Vifor Fresenius Medical Care Renal Pharma (GNHAF) announce that the EMA has accepted to review the Marketing Authorization Application ((MAA)) for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis pat...

Under Priority review, the FDA has accepted Cara Therapeutics (CARA) and Vifor Pharma's (GNHAF) New Drug Application ((NDA)) for Korsuva (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.The PDUFA target action date is August 23, ...

Vifor Pharma AG (GNHAF) Q4 2020 Results Earnings Conference Call March 3, 2021, 08:00 AM ET Company Participants Colin Bond - Chief Financial Officer Stefan Schulze - Chief Executive Officer Conference Call Participants Daniel Wendorff - Commerzbank Christian Glennie - Stifel Rosie Turner - B...

The following slide deck was published by Vifor Pharma AG in conjunction with their 2020 Q4 earnings call. For further details see: Vifor Pharma AG 2020 Q4 - Results - Earnings Call Presentation